KALA - Kala Pharmaceuticals, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Watertown,
United States
Type: Equity
KALA price evolution
KALA
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $50.9 | $56.06 | $49.26 | $63.64 |
| Short term investments | $9.92 | |||
| Net receivables | $0.24 | $0.3 | $0.29 | $0.4 |
| Inventory | ||||
| Total current assets | $52.87 | $57.9 | $65.53 | $71.34 |
| Long term investments | $0.3 | $0.31 | $0.33 | $0.37 |
| Property, plant & equipment | $2.78 | $2.9 | $0.64 | $0.51 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $3.08 | $3.22 | $0.96 | $0.88 |
| Total investments | $0.3 | $0.31 | $10.25 | $0.37 |
| Total assets | $55.95 | $61.12 | $66.5 | $72.23 |
| Current liabilities | ||||
| Accounts payable | $0.92 | $0.79 | $0.76 | $1 |
| Deferred revenue | $1.07 | $2.93 | ||
| Short long term debt | $0.33 | $0.32 | $0 | |
| Total current liabilities | $8.35 | $10.3 | $9.85 | $10.27 |
| Long term debt | $35.99 | $35.76 | $33.57 | $33.27 |
| Total noncurrent liabilities | $40.1 | $39.6 | $39.16 | $38.5 |
| Total debt | $36.32 | $36.08 | $33.57 | $33.27 |
| Total liabilities | $48.45 | $49.9 | $49.01 | $48.77 |
| Shareholders' equity | ||||
| Retained earnings | -$629.41 | -$620.78 | -$612.08 | -$601.66 |
| Other shareholder equity | $0 | $0.01 | ||
| Total shareholder equity | $7.5 | $11.22 | $17.49 | $23.46 |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $50.9 | $70.5 | $94.18 | $77.26 |
| Short term investments | $76.28 | |||
| Net receivables | $0.24 | $1.1 | $15.35 | $9.6 |
| Inventory | $18.22 | $11.45 | ||
| Total current assets | $52.87 | $85.94 | $124.37 | $171.38 |
| Long term investments | $0.3 | $0.46 | $1.46 | $12.99 |
| Property, plant & equipment | $2.78 | $0.42 | $4.02 | $31.02 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $3.08 | $0.88 | $15.06 | $50.23 |
| Total investments | $0.3 | $0.46 | $1.46 | $89.27 |
| Total assets | $55.95 | $86.82 | $139.43 | $221.61 |
| Current liabilities | ||||
| Accounts payable | $0.92 | $2.83 | $4.9 | $1.72 |
| Deferred revenue | $1.07 | |||
| Short long term debt | $0.33 | $5.01 | $0.71 | $1.53 |
| Total current liabilities | $8.35 | $25.68 | $37.42 | $22.23 |
| Long term debt | $35.99 | $37.94 | $79.48 | $99.39 |
| Total noncurrent liabilities | $40.1 | $42.16 | $85.2 | $99.39 |
| Total debt | $36.32 | $42.95 | $80.19 | $100.92 |
| Total liabilities | $48.45 | $67.85 | $122.62 | $121.61 |
| Shareholders' equity | ||||
| Retained earnings | -$629.41 | -$587.21 | -$542.39 | -$399.78 |
| Other shareholder equity | $0 | |||
| Total shareholder equity | $7.5 | $18.97 | $16.8 | $100 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | ||||
| Cost of revenue | ||||
| Gross Profit | ||||
| Operating activities | ||||
| Research & development | $4.72 | $5.55 | $4.28 | $4.04 |
| Selling, general & administrative | $4.62 | $4.95 | $4.96 | $6.03 |
| Total operating expenses | $9.34 | $10.51 | $9.24 | $9.84 |
| Operating income | -$9.34 | -$10.51 | -$9.24 | -$9.84 |
| Income from continuing operations | ||||
| EBIT | -$7.16 | -$7.25 | -$9 | -$12.98 |
| Income tax expense | ||||
| Interest expense | $1.47 | $1.46 | $1.41 | $1.47 |
| Net income | ||||
| Net income | -$8.63 | -$8.7 | -$10.41 | -$14.46 |
| Income (for common shares) | -$8.63 | -$8.7 | -$10.41 | -$14.46 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $3.89 | $11.24 | $6.36 | |
| Cost of revenue | $2.56 | $4.1 | $3.17 | |
| Gross Profit | $1.33 | $7.14 | $3.19 | |
| Operating activities | ||||
| Research & development | $18.59 | $17.65 | $11.52 | $18.35 |
| Selling, general & administrative | $20.57 | $65.03 | $105.06 | $81.07 |
| Total operating expenses | $38.92 | $83.33 | $137.39 | $99.42 |
| Operating income | -$38.92 | -$81.99 | -$130.25 | -$96.23 |
| Income from continuing operations | ||||
| EBIT | -$36.38 | -$37.56 | -$134.22 | -$95.74 |
| Income tax expense | ||||
| Interest expense | $5.81 | $7.27 | $8.38 | $8.59 |
| Net income | ||||
| Net income | -$42.2 | -$44.82 | -$142.6 | -$104.33 |
| Income (for common shares) | -$42.2 | -$44.82 | -$142.6 | -$104.33 |
| (in millions $) | 31 Dec 2023 | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Net income | -$8.63 | -$8.7 | -$10.41 | -$14.46 |
| Operating activities | ||||
| Depreciation | $0.15 | $0.16 | $0.08 | $0.09 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $2.37 | $2.4 | $1.36 | $1.32 |
| Total cash flows from operations | -$7.7 | -$2.95 | -$7.59 | -$9.68 |
| Investing activities | ||||
| Capital expenditures | -$0.01 | -$0.28 | -$0.17 | -$0.11 |
| Investments | $10 | -$9.87 | ||
| Total cash flows from investing | -$0.01 | $9.72 | -$10.03 | -$0.11 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.57 | $0.04 | $3.07 | $14.9 |
| Net borrowings | -$10 | |||
| Total cash flows from financing | $2.54 | $0.04 | $3.07 | $2.86 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$5.17 | $6.81 | -$14.55 | -$6.93 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$42.2 | -$44.82 | -$142.6 | -$104.33 |
| Operating activities | ||||
| Depreciation | $0.47 | $0.98 | $2.31 | $2.84 |
| Business acquisitions & disposals | $62.91 | -$4.65 | ||
| Stock-based compensation | $7.46 | $7.01 | $16.09 | $13.31 |
| Total cash flows from operations | -$27.93 | -$78.91 | -$108.23 | -$90.69 |
| Investing activities | ||||
| Capital expenditures | -$0.56 | -$0.2 | -$0.79 | -$1.94 |
| Investments | $0.13 | $0.01 | $76.25 | -$76.27 |
| Total cash flows from investing | -$0.43 | $62.72 | $70.8 | -$78.21 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $18.58 | $32.1 | $42.82 | $160.66 |
| Net borrowings | -$10 | -$40.04 | -$0.26 | -$0.03 |
| Total cash flows from financing | $8.51 | -$7.94 | $42.55 | $160.63 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$19.85 | -$24.13 | $5.12 | -$8.28 |
News
Fundamentals
| Market cap | $17.66M |
|---|---|
| Enterprise value | $3.09M |
| Shares outstanding | 2.76M |
| Revenue | $0.00 |
|---|---|
| EBITDA | -$35.91M |
| EBIT | -$36.38M |
| Net Income | -$42.20M |
| Revenue Q/Q | N/A |
| Revenue Y/Y | -100.00% |
| P/E ratio | -0.42 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | -0.09 |
| EV/EBIT | -0.08 |
| P/S ratio | N/A |
| P/B ratio | 2.35 |
| Book/Share | 2.72 |
| Cash/Share | 18.44 |
| EPS | -$15.29 |
|---|---|
| ROA | -65.99% |
| ROE | -282.84% |
| Debt/Equity | 6.46 |
|---|---|
| Net debt/EBITDA | 0.07 |
| Current ratio | 6.33 |
| Quick ratio | 6.33 |